New program aims to keep cancer patients on treatment by spotting side effects sooner

NCT ID NCT06693687

Recruiting now Symptom relief Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This study tests the ApricityCare program, which helps people with metastatic cancer and their doctors spot treatment side effects early. The goal is to manage these side effects quickly so patients can stay on their cancer therapy longer. About 425 adults starting systemic cancer therapy will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ApricityCare program (behavioral intervention for early detection and management of treatment side effects)
What this could lead to: If it works, this could help people with metastatic cancer stay on their treatment longer by catching and managing side effects early.
What could go wrong: This is an early study without a control group, so it's unclear if the program truly reduces treatment stops. Results may not apply to all cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

kidney cancer metastatic malignant neoplasm Neoplasm Metastasis prostate cancer urinary bladder carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CANCER

Contacts and locations

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.